Literature DB >> 20639188

Kynurenine and its metabolites in Alzheimer's disease patients.

E Gulaj1, K Pawlak, B Bien, D Pawlak.   

Abstract

PURPOSE: The kynurenine pathway (KP) is a major route of tryptophan metabolism. Several metabolites of this pathway are proposed to be involved in the pathogenesis of Alzheimer's disease. The aim of this study was to evaluate peripheral KP in patients with Alzheimer type dementia and a detailed analysis of correlation between kynurenine (KYN), kynurenic acid (KYNA), 3-hydroxykynurenine (3-HK), anthranilic acid (AA), quinolinic acid (QUIN) and degree of neuropsychological changes in AD. MATERIAL/
METHODS: The plasma concentration of tryptophan and its products degradation by kynurenine pathway were analyzed in 34 patients suffering from Alzheimer type dementia and 18 controls in similar age using high-performance liquid chromatography technique.
RESULTS: In demented patients we found lower tryptophan and KYNA concentrations. There was a non-significant increase of KYN, 3-HK and AA levels, and a Marked increase of QUIN in Alzheimer's disease group. We observed positive correlations between cognitive function tests and plasma KYNA levels, and inversely correlations between these tests and QUIN levels in Alzheimer type dementia.
CONCLUSIONS: Increased TRP degradation and simultaneous altered kynurenines levels were found in plasma of AD patients. It proves activation of peripheral kynurenine pathway in this type of dementia. The alterations of two main KYN metabolites: KYNA and QUIN seem to be associated with the impairment of the cognitive function in AD patients. This appears to offer Novel therapeutic opportunities, with the development of new compounds as a promising perspective for brain neuroprotection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20639188     DOI: 10.2478/v10039-010-0023-6

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN: 1896-1126            Impact factor:   3.287


  83 in total

Review 1.  Pre-treatment effects of peripheral tumors on brain and behavior: neuroinflammatory mechanisms in humans and rodents.

Authors:  Andrew Schrepf; Susan K Lutgendorf; Leah M Pyter
Journal:  Brain Behav Immun       Date:  2015-05-06       Impact factor: 7.217

2.  Urinary kynurenine as a biomarker for Parkinson's disease.

Authors:  Jia-He Bai; Ya-Li Zheng; Yong-Peng Yu
Journal:  Neurol Sci       Date:  2020-07-13       Impact factor: 3.307

3.  Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study.

Authors:  Vincent Chouraki; Sarah R Preis; Qiong Yang; Alexa Beiser; Shuo Li; Martin G Larson; Galit Weinstein; Thomas J Wang; Robert E Gerszten; Ramachandran S Vasan; Sudha Seshadri
Journal:  Alzheimers Dement       Date:  2017-06-08       Impact factor: 21.566

Review 4.  Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets.

Authors:  Francis J Herman; Sherry Simkovic; Giulio M Pasinetti
Journal:  Br J Pharmacol       Date:  2019-03-21       Impact factor: 8.739

5.  UHPLC-QTOF/MS-based metabolomics investigation for the protective mechanism of Danshen in Alzheimer's disease cell model induced by Aβ1-42.

Authors:  Mingyong Zhang; Yue Liu; Min Liu; Biying Liu; Na Li; Xin Dong; Zhanying Hong; Yifeng Chai
Journal:  Metabolomics       Date:  2019-01-17       Impact factor: 4.290

Review 6.  Role of Adiposity-Driven Inflammation in Depressive Morbidity.

Authors:  Lucile Capuron; Julie Lasselin; Nathalie Castanon
Journal:  Neuropsychopharmacology       Date:  2016-07-11       Impact factor: 7.853

7.  Pharmacological characterization of cultivated neuronal networks: relevance to synaptogenesis and synaptic connectivity.

Authors:  Peter Verstraelen; Isabel Pintelon; Rony Nuydens; Frans Cornelissen; Theo Meert; Jean-Pierre Timmermans
Journal:  Cell Mol Neurobiol       Date:  2014-04-19       Impact factor: 5.046

8.  Targeting inflammation to influence cognitive function following spinal cord injury: a randomized clinical trial.

Authors:  D J Allison; A R Josse; D A Gabriel; P Klentrou; D S Ditor
Journal:  Spinal Cord       Date:  2016-06-21       Impact factor: 2.772

9.  Peripheral Tryptophan - Kynurenine Metabolism Associated with Metabolic Syndrome is Different in Parkinson's and Alzheimer's Diseases.

Authors:  Gregory Oxenkrug; Marieke van der Hart; Julien Roeser; Paul Summergrad
Journal:  Endocrinol Diabetes Metab J       Date:  2017-11-19

10.  Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice.

Authors:  Nathaniel S Woodling; Damien Colas; Qian Wang; Paras Minhas; Maharshi Panchal; Xibin Liang; Siddhita D Mhatre; Holden Brown; Novie Ko; Irene Zagol-Ikapitte; Marieke van der Hart; Taline V Khroyan; Bayarsaikhan Chuluun; Prachi G Priyam; Ginger L Milne; Arash Rassoulpour; Olivier Boutaud; Amy B Manning-Boğ; H Craig Heller; Katrin I Andreasson
Journal:  Brain       Date:  2016-05-13       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.